Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

tract and period costs related to production.  The reduction in the gross margin rate is due to a $3.9 million provision for XIAFLEX inventory that may expire in 2011 prior to expected future sales to customers, and lower amortization in 2010 of deferred milestone payments, partially offset by the contribution of high margin XIAFLEX product sales and the impact of year-over-year price increases on U.S. Testim revenues.

Research and development spending for the quarter ended December 31, 2010 was $14.0 million, compared to $11.4 million for 2009.  The increase in expense results principally from the commencement of start-up activities related to the phase III XIAFLEX clinical trials for Peyronie's disease and costs related to development of a larger scale XIAFLEX production process.  

Selling, general and administrative costs for the quarter ended December 31, 2010 were $47.0 million, compared to $38.7 million in the comparable 2009 period.  The increase was primarily due to the addition of the sales and reimbursement field force and infrastructure, and promotional and training activity in support of the launch of XIAFLEX for Dupuytren's in the U.S., and higher non-cash stock-based compensation expense.

As of December 31, 2010, Auxilium had $128.2 million in cash, cash equivalents and short-term investments, compared to $142.4 million at September 30, 2010.

2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the full year 2010: Year EndYear EndIncrease12/31/201012/31/2009 (Decrease)Testim U.S. Revenue

$190.0$152.025%Testim Ex – U.S. & Contract Revenue

3.08.5(64%)Total Testim Revenue

$193.0$160.520%XIAFLEX U.S. Revenue

$14.1-n/aXIAFLEX Contract Revenue

4.33.622%Total XIAFLEX Revenue

$18.4$3.6417%Total Worldwide Revenue

$211.4$164.029%Contract Revenues represent amortization of previously receive
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... According to the International Atomic Energy Agency (IAEA) ... terrorists acquiring sufficient quantities of plutonium or highly ... explosive device. The IAEA also notes that most ... quantities, which can be challenging to detect with ... study appearing this week in the Journal ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2
... , RESEARCH TRIANGLE PARK, N.C. , May 4 ... therapeutics, announced today that Kenneth I. Moch has ... Chimerix as Chief Operating Officer in July 2009 , ... and financing biomedical companies.  Mr. Moch will also join the ...
... May 4 PharmAthene, Inc. (NYSE Amex: PIP ), ... today announced that the Company,s Interim CEO, Eric I. Richman ... the critical interrelationship between government, academia and industry in the development ... , , ...
... Packing Record Tetrahedral dice, which have four ... yet tested, according to research performed by a collaboration ... revelation is the result of a series of experiments ... and adding more dice until the containers were completely ...
Cached Biology Technology:Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 2Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 3Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 4PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference 2Densest dice packing and computing with molecules 2
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... 3, 2014 Research and Markets ( ... "Global Gesture Recognition & Touch-Less Sensing (2D, ... 2020" report to their offering ... Recognition & Touch-Less Sensing Market to Grow Exponentially. ... while, but the companies were unable to leverage ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... NJ, March 20, 2013, John Wiley & Sons, Inc., ... Society (SPPS); a partnership which began over sixty years ... research journal Physiologia Plantarum , an international thought ... partnership began in 1948 when the society, known then ...
... uncovered from poorly explored areas of the Peruvian jungles. The ... before a dark brown and black background. It is assumed ... a slight difference in altitude ranges, which makes their biological ... was published in the open access journal Zookeys ...
... of the natural motors that are serving as models for ... therapeutic DNA, RNA or drugs into individual diseased cells. Their ... bacteria-killing virus and a new way to move DNA ... journal ACS Nano . Peixuan Guo and colleagues ...
Cached Biology News:The Scandinavian Plant Physiology Society and Wiley extend over 60 years of partnership 2Peru surprises with 2 new amazing species of woodlizards 2
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... component of the COP9 signalosome complex (CSN), ... developmental processes. The CSN complex is an ... pathway by mediating the deneddylation of the ... The complex is also involved in phosphorylation ...
... STAR3000 HISTAR detection systems provide linking ... used with species specific primary antibodies ... specimens. Visualisation is accomplished using an ... novel polymer labelling technology. Secondary antibodies ...
Biology Products: